His primary scientific interests are in Stereochemistry, Biochemistry, Organic chemistry, Receptor and Antagonist. His studies in Stereochemistry integrate themes in fields like Aliphatic compound, Active site, Dipeptide, Aspergillus clavatus and Tryptoquivaline. His work in the fields of Biochemistry, such as Phosphatase, Inositol and Inositol monophosphatase, overlaps with other areas such as Metal Binding Site and Proteoglycan.
His research in the fields of Nuclear magnetic resonance spectroscopy and Cyclobutane overlaps with other disciplines such as Moniliformin. His study in the field of Peptide hormone and GABAA receptor also crosses realms of Arginine. James P. Springer interconnects Imidazole, Diazepam, Benzodiazepine, Cholecystokinin and Drug discovery in the investigation of issues within Antagonist.
His scientific interests lie mostly in Stereochemistry, Organic chemistry, Medicinal chemistry, Stereoselectivity and Crystal structure. Borrowing concepts from X-ray crystallography, James P. Springer weaves in ideas under Stereochemistry. His work on Organic chemistry deals in particular with Lithium, Aliphatic compound, Lactone, Tetronic acid and Alkylation.
He usually deals with Medicinal chemistry and limits it to topics linked to Iminium and Aldehyde. James P. Springer works mostly in the field of Crystal structure, limiting it down to topics relating to Molecule and, in certain cases, Crystallography. His Ketone study integrates concerns from other disciplines, such as Epoxy and Diterpene.
James P. Springer spends much of his time researching Stereochemistry, Organic chemistry, Medicinal chemistry, Stereoselectivity and Antagonist. His work in the fields of Stereochemistry, such as Bicyclic molecule, Diastereomer, Lactam and Nuclear magnetic resonance spectroscopy, intersects with other areas such as X-ray crystallography. His Medicinal chemistry research includes themes of Iminium, Aryl, Nucleophile and Acid catalysis.
His Stereoselectivity study combines topics from a wide range of disciplines, such as Sigmatropic reaction, Allylic rearrangement, Cycloaddition and Cope rearrangement. Antagonist is a subfield of Receptor that he investigates. James P. Springer combines subjects such as Oxytocin Antagonist, Anxiolytic, Drug discovery and GABAA receptor with his study of Peptide hormone.
His primary areas of study are Stereochemistry, Organic chemistry, Antagonist, Biochemistry and Receptor. In the subject of general Stereochemistry, his work in Diastereomer and Lactam is often linked to Infrared and X-ray crystallography, thereby combining diverse domains of study. The Antagonist study combines topics in areas such as Cholecystokinin, Imidazole, Benzodiazepine and Substituent.
James P. Springer has researched Cholecystokinin in several fields, including Drug discovery and GABAA receptor. In his works, James P. Springer performs multidisciplinary study on Biochemistry and Metal Binding Site. The various areas that he examines in his Receptor study include Endocrinology, Oxadiazole and Diazepam.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.
A W Alberts;J Chen;G Kuron;V Hunt.
Proceedings of the National Academy of Sciences of the United States of America (1980)
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists
B. E. Evans;K. E. Rittle;M. G. Bock;R. M. DiPardo.
Journal of Medicinal Chemistry (1988)
Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
Manuel A. Navia;Paula M. D. Fitzgerald;Brian M. McKeever;Chih-Tai Leu.
On the use of the O-methylmandelate ester for establishment of absolute configuration of secondary alcohols
Barry M. Trost;John L. Belletire;Stephen Godleski;Patrick G. McDougal.
Journal of Organic Chemistry (1986)
Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme
Joseph W. Becker;Alice I. Marcy;Laura L. Rokosz;Melinda G. Axel.
Protein Science (1995)
Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution.
P. M. D. Fitzgerald;B. M. Mckeever;J. F. Vanmiddlesworth;J. P. Springer.
Journal of Biological Chemistry (1990)
Structure of human neutrophil elastase in complex with a peptide chloromethyl ketone inhibitor at 1.84-A resolution
Manuel A. Navia;Brian M. McKeever;James P. Springer;Tsau-Yen Lin.
Proceedings of the National Academy of Sciences of the United States of America (1989)
Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma.
Baldwin Jj;Ponticello Gs;Anderson Ps;Christy Me.
Journal of Medicinal Chemistry (1989)
The NMR structure of the inhibited catalytic domain of human stromelysin-1.
Paul R. Gooley;John F. O'Connell;Alice I. Marcy;Gregory C. Cuca.
Nature Structural & Molecular Biology (1994)
Structure of inositol monophosphatase, the putative target of lithium therapy.
Roger Bone;James P. Springer;John R. Atack.
Proceedings of the National Academy of Sciences of the United States of America (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: